Morihara Hirofumi

Affiliation and department：

Research field (2)： Pathobiochemistry , Pharmacology

Research keywords (6)：腫瘍循環器 , ハイスループットスクリーニング , 創薬 , 遺伝性疾患 , 病態モデル , iPS細胞

Research theme for competitive and other funds (7)：

2022 - 2025 Establishment and mechanistic analysis of a model of cardiac dysfunction caused by molecular-targeted cancer drugs
2022 - 2025 The cell-based vascular model with the inducible pluripotent stem cells of Marfan syndrome.
2023 - 2024 心不全時の心骨格筋連関における TMEM182 の病態的役割の解明
2022 - 2023 筋肉特異的に発現する機能未知膜蛋白質 TMEM182 の生理学的・病態学的役割の解明
2021 - 2022 紫外線誘発性の皮膚表皮傷害に対する新規治療及び予防薬の探索

Show all

Papers (9)：

Mahito Matsuno, Shunichi Yokoe, Takehiro Nagatsuka, Hirofumi Morihara, Kazumasa Moriwaki, Michio Asahi. O-GlcNAcylation-induced GSK-3β activation deteriorates pressure overload-induced heart failure via lack of compensatory cardiac hypertrophy in mice. Frontiers in Endocrinology. 2023. 14
Mime Kobayashi, Kiichiro Tomoda, Hirofumi Morihara, Michio Asahi, Tetsuji Shimizu, Shinya Kumagai. Non-thermal atmospheric-pressure plasma potentiates mesodermal differentiation of human induced pluripotent stem cells. Heliyon. 2022. 8. 12. e12009-e12009
Atsushi Daimon, Hirofumi Morihara, Kiichiro Tomoda, Natsuko Morita, Yoshinori Koishi, Kazuyoshi Kanki, Masahide Ohmichi, Michio Asahi. Intravenously Injected Pluripotent Stem Cell-derived Cells Form Fetomaternal Vasculature and Prevent Miscarriage in Mouse. Cell Transplantation. 2020. 29. 096368972097045-096368972097045
Kenjiro Tsuruoka, Shigeo Wakabayashi, Hirofumi Morihara, Ninso Matsunaga, Yasuhito Fujisaka, Isao Goto, Akihisa Imagawa, Michio Asahi. Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. International journal of cardiology. 2020. 313. 67-75
Shigeo Wakabayashi, Hirofumi Morihara, Shunichi Yokoe, Takatoshi Nakagawa, Kazumasa Moriwaki, Kiichiro Tomoda, Michio Asahi. Overexpression of Na+/H+ exchanger 1 specifically induces cell death in human iPS cells via sustained activation of the Rho kinase ROCK. The Journal of biological chemistry. 2019. 294. 51. 19577-19588

ｍore...

Patents (1)：

Gb3 蓄積起因性疾患の予防又は治療剤

Lectures and oral presentations (10)：

TMEM182 は integrin-linked kinase を増加させることで Wnt/β-catenin シグナルの活性化状態を維持しヒトiPS細胞の心筋分化を抑制する
(第33回日本循環薬理学会 2024)
TMEM182 maintains the activated state of Wnt/β-catenin signaling by increasing ILK and inhibits cardiac differentiation in human iPS cells
(The 96th Annual Meeting of the Japanese Pharmacological Society 2022)
Effect of TMEM182, a novel membrane protein, on muscle differentiation
(The 95th Annual Meeting of the Japanese Pharmacological Society 2022)
Lysosomal Regulation of mTOR-AKT Signaling via the Vacuolar-type H+- ATPase
(The 93rd Annual Meeting of the Japanese Pharmacological Society 2020)
Modeling Anderson-Fabry Disease with Human iPSCs Reveals Pathogenic Glycosphingolipid-Induced Cardiac Abnormalities
(The 92nd Annual Meeting of the Japanese Pharmacological Society 2019)

ｍore...

Education (2)：

2013 - 2017 Osaka University
2007 - 2013 Osaka University of Pharmaceutical Sciences

Professional career (1)：

博士 (薬学) (大阪大学)

Work history (2)：

2021/04 - 現在 Osaka Medical and Pharmaceutical University
2017/04 - 2021/03 Osaka Medical College

Association Membership(s) (3)：

日本循環薬理学会 , THE PHARMACEUTICAL SOCIETY OF JAPAN , THE JAPANESE PHARMACOLOGICAL SOCIETY

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page